7月21日A股投資避雷針︱退市錦港:7月25日終止上市暨摘牌;耀皮玻璃:股東中國復材擬大宗交易減持不超2%股份
新炬網絡股東上海森梟擬減持不超1.50%股份;華大九天大股東大基金、上海建元擬減持合計不超1.5%股份;迦南科技控股股東迦南集團、董事黃斌斌擬減持合計不超3.338%股份;惠雲鈦業控股股東、實控人及一致行動人擬減持合計不超3%股份;綠通科技股東創鈺銘晨及其一致行動人擬合計減持不超3.42%股份;鼎勝新材股東普潤平方及普潤平方壹號擬合計減持不超3%股份;紅寶麗第一大股東寶源投資、實控人芮敬功擬減持合計不超2%股份;耀皮玻璃股東中國復材擬大宗交易減持不超2%股份;退市錦港7月25日終止上市暨摘牌;諾泰生物實施其他風險警示 7月21日停牌1天

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.